Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — BioShares July 2024
17 slides from Argenica Therapeutics's conference presentation, July 2024
Slide 1: Argenica Therapeutics Investor Presentation
ARGENICA THERAPEUTICS INVESTOR PRESENTATION ASX: AGN MANAGING DIRECTOR PRESENTATION BIOSHARES JULY 2024 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Our Lead Drug Candidate
OUR LEAD DRUG CANDIDATE DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Efficacy Safety / Tox STROKE ABOUT ARG-007 Damage to the brain from interruption of its blood supply Cationic poly-arginine peptide HIE ARGENICA THERAPEUTICS Hypoxic ischemic encephalopathy (HIE) Multiple mechanisms of action dev
Slide 5: Key Company Metrics
KEY COMPANY METRICS $6.6M $12M +$4M CASH @ BANK1 PLACEMENT COMPLETED NON-DILUTIVE GRANTS 2 ARGENICA THERAPEUTICS 122.8M $111M DOSING SHARES ON ISSUE3 MARKET CAP4 IN PHASE 2 TRIAL UNDERWAY 1. Cash balance as @ 31 March 2023 2. Various ASX Announcements dated 20 January 2023, 22 March 2023, 30 March 2
Slide 6: Enhancing Stroke Recovery with ARG-007
ENHANCING ARGENICA THERAPEUTICS STROKE RECOVERY WITH ARG-007 6 www.argenica.com.au
Slide 7: Ischemic Stroke
ISCHEMIC STROKE EXAMPLE HOW ARG-007 WORKS IN STROKE ARGENICA THERAPEUTICS INITIAL INFARCTION SETS OFF A CASCADE OF CELL DEATH THAT WILL CONTINUE SPREADING FROM LOCATION ARG-007 STOPS THE CASCADE OF CELL DEATH & PROVIDES A PROTECTION BARRIER AROUND ITHE INITIAL INFARCTION 7 www.argenica.com.au ARG-00
Slide 8: Competitors – Assessment in Excitotoxicity Model
COMPETITORS – ASSESSMENT IN EXCITOTOXICITY MODEL Neurons are bathed in glutamate to reflect excitotoxicity seen in stroke. The MTS assay measures cell viability follow glutamate exposure and drug treatment. Note R18-OH is ARG-007 and R10 is the smaller polyarginine, but similar to ARG-007. ARGENICA
Slide 9: Encouraging Stroke Results to Date
ENCOURAGING STROKE RESULTS TO DATE SUCCESSFUL PHASE 28 Days 1 (HUMAN after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE FIE
Slide 10: SEANCON Phase 2 Clinical Trial in Stroke Overview
“SEANCON” PHASE 2 CLINICAL TRIAL IN STROKE OVERVIEW Highest dose from Phase 1 trial taken into Phase 2 10 Australian hospitals recruiting 92 patients – based on preclinical & clinical studies Study size selected based on preclinical NHP1 data and similar ARGENICA THERAPEUTICS Double-blinded, randomi
Slide 11: Phase 2 Enrolment
PHASE 2 ENROLMENT 92 participants to be enrolled across 10 stroke centres in Australia: ARGENICA THERAPEUTICS 11 www.argenica.com.au
Slide 12: Phase 2 Trial Design in Acute Ischaemic Stroke
PHASE 2 TRIAL DESIGN IN ACUTE ISCHAEMIC STROKE ARGENICA THERAPEUTICS PATIENT HAS PATIENT IN ARRIVES AT DIAGNOSE THROMBECTOMY AMBULANCE HOSPITAL STROKE TYPE REHAB BEGINS A STROKE Initial screening of Administration of Endpoints patients to meet inclusion 0.3mg/kg ARG-007 or Mortality rate and frequen
Slide 13: Protecting Still Salvagable Brain Tissue (Penumbra)
PROTECTING STILL SALVAGABLE BRAIN TISSUE (PNUMBRA) ARGENICA THERAPEUTICS 13 www.argenica.com.au Zhou Y, et al, Reperfusion Injury Is Associated With Poor Outcome in Patients With Recanalization After Thrombectomy. Stroke. 2023 Jan;54(1):96-104.
Slide 14: Key Exclusion Criteria – ASPECTS
KEY EXCLUSION CRITERIA – ASPECTS 0 - 5 ARGENICA THERAPEUTICS 14 Sourced from - https://epos.myesr.org/posterimage/esr/ecr2023/163394/mediagallery/948704?deliveroriginal=1 www.argenica.com.au
Slide 15: Near-Term Catalysts
NEAR-TERM CATALYSTS Quarterly ARGENICA THERAPEUTICS Phase 2 Trial Updates Q4 CY24 Investigational New Drug Application to be submitted to the FDA Q1-Q3 CY25 Prepare Fast Track Regulatory Submissions Q3 CY24 – Q4 CY25 Preclinical data for HIE, TBI and AD 15 www.argenica.com.au
Slide 16: Clear Near-Term Catalysts
3# CLEAR NEAR- TERM CATALYSTS A number of clinical and preclinical data points will be generated over the next 12 months, providing significant upside to investors. ARGENICA THERAPEUTICS 1# SOLVING LARGE UNMET NEEDS 2# Nervous system disorders are the SIGNIFICANT PRE- 4# biggest cause of poor health
Slide 17: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 17 www.argenica.com.au